IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Aisling Capital Management LP

Q4 2019 Holdings

Filed 2020-02-06 | 13 holdings | $139.1M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
BridgeBio (Bbio)(BBIO)COM10806X102$134.4M3,835,72296.6%
Arcus Biosciences, Inc. (Rcus)(RCUS)COM03969F109$3.4M333,3332.4%
Aclaris Theraputics Inc (Acrs)(ACRS)COM00461U105$1.2M634,4550.9%
Eidos Therapeutics, Inc. (Eidix)(EIDXGBP)COM28249H104$64.5K1,123,6300.0%
Avrobio, Inc. (Avro)COM05455M100$18.0K893,0790.0%
Aeglea Biotherapeutics Inc (Agle)(AGLEUSD)COM00773J103$9.9K1,291,1510.0%
Atreca (Bcel)(BCELUSD)CL A COM04965G109$6.0K387,6530.0%
Marker Therapeutics, Inc. (Mrkr)COM57055L107$5.8K2,000,0000.0%
ObsEva SA (Obsv)COMH5861P103$5.3K1,386,3380.0%
Zosano Pharma Corporation (Zsan)COM98979H202$4.1K2,718,2260.0%
Sunesis Pharmaceuticals, Inc. (Snss)COM867328700$3.4K10,100,0000.0%
Verona Pharma plc (Vrna)(VRNA)COM925050106$2.6K443,5960.0%
Nabriva Therapeutics plc (Nbrv)SHSG63637105$2.5K1,910,2870.0%